Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety and Immunogenicity of V710 in Adults With Kidney Disease on Hemodialysis (V710-005)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with end stage kidney disease and is on hemodialysis~* Female patients who are able to have children must have a negative urine pregnancy tests~Exclusion Criteria:~* Developed a serious infection within the past 12 months; allergy to the components of the vaccine~* Has been vaccinated with a live virus within the past 30 days or are scheduled to be vaccinated with a live virus in the next 60 days~* Received V710 vaccine before

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- V710 - Group 1 (Type: EXPERIMENTAL): V710 (60 mcg without MAA) on Day 1 and Day 28 followed by third dose of V710 or placebo on Day 180.
- V710 - Group 2 (Type: EXPERIMENTAL): V710 (60 mcg without MAA) on Day 1 and Placebo on Day 28 followed by third dose of V710 or placebo on Day 180.
- V710 - Group 3 (Type: EXPERIMENTAL): V710 (60 mcg with MAA) on Day 1 and Day 28 followed by third dose of V710 or placebo on Day 180.
- V710 - Group 4 (Type: EXPERIMENTAL): V710 (60 mcg with MAA) on Day 1 and Placebo on Day 28 followed by third dose of V710 or placebo on Day 180.
- V710 - Group 5 (Type: EXPERIMENTAL): V710 (90 mcg with MAA) on Day 1 and Day 28 followed by third dose of V710 or placebo on Day 180.
- Group 6 (Type: PLACEBO_COMPARATOR): Placebo on Day 1, 28 and 180.

Based on this trial design, predict the completion outcome and termination type (if applicable).